Raymond Stevens, Structure Therapeutics CEO
Behind Friday's $161M IPO: A star scientist, GPCR drug discovery and a plan to challenge pharma in diabetes
What does it take to pull off a $161 million biotech IPO these days?
In Structure Therapeutics’ case, it means having a star scientist co …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
